Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.
Identifieur interne : 002A50 ( Main/Curation ); précédent : 002A49; suivant : 002A51Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.
Auteurs : Min Zhuang [Japon] ; Hong Jiang ; Yasuhiro Suzuki ; Xiaoguang Li ; Peng Xiao ; Takashi Tanaka ; Hong Ling ; Baofeng Yang ; Hiroki Saitoh ; Lianfeng Zhang ; Chuan Qin ; Kazuo Sugamura ; Toshio HattoriSource :
- Antiviral research [ 1872-9096 ] ; 2009.
Descripteurs français
- KwdFr :
- Butanols (), Humains, Lignée cellulaire, Médicaments issus de plantes chinoises (), Médicaments issus de plantes chinoises (pharmacologie), Plantes médicinales (), Proanthocyanidines (), Proanthocyanidines (pharmacologie), Régulation négative, Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (physiologie).
- MESH :
- pharmacologie : Médicaments issus de plantes chinoises, Proanthocyanidines.
- physiologie : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- virologie : Syndrome respiratoire aigu sévère.
- Butanols, Humains, Lignée cellulaire, Médicaments issus de plantes chinoises, Plantes médicinales, Proanthocyanidines, Régulation négative, Virus du SRAS.
English descriptors
- KwdEn :
- Butanols (chemistry), Cell Line, Down-Regulation, Drugs, Chinese Herbal (chemistry), Drugs, Chinese Herbal (pharmacology), Humans, Plants, Medicinal (chemistry), Proanthocyanidins (chemistry), Proanthocyanidins (pharmacology), SARS Virus (drug effects), SARS Virus (physiology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , chemistry : Butanols, Drugs, Chinese Herbal, Proanthocyanidins.
- chemical , pharmacology : Drugs, Chinese Herbal, Proanthocyanidins.
- chemistry : Plants, Medicinal.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- physiology : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Cell Line, Down-Regulation, Humans.
Abstract
We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC(50S), 283.4+/-16.3 and 149.5+/-13.5 microg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC(50S), 43.1+/-2.8 and 7.8+/-0.3 microg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC(50S), 29.9+/-3.3 and 41.3+/-3.4 microM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.
DOI: 10.1016/j.antiviral.2009.02.001
PubMed: 19428598
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001906
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001906
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001814
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001F11
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001F11
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001F11
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002A97
Links to Exploration step
pubmed:19428598Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.</title>
<author><name sortKey="Zhuang, Min" sort="Zhuang, Min" uniqKey="Zhuang M" first="Min" last="Zhuang">Min Zhuang</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University, 980-8574, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University, 980-8574</wicri:regionArea>
<orgName type="university">Université du Tōhoku</orgName>
<placeName><settlement type="city">Sendai</settlement>
<region type="province">Région de Tōhoku</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jiang, Hong" sort="Jiang, Hong" uniqKey="Jiang H" first="Hong" last="Jiang">Hong Jiang</name>
</author>
<author><name sortKey="Suzuki, Yasuhiro" sort="Suzuki, Yasuhiro" uniqKey="Suzuki Y" first="Yasuhiro" last="Suzuki">Yasuhiro Suzuki</name>
</author>
<author><name sortKey="Li, Xiaoguang" sort="Li, Xiaoguang" uniqKey="Li X" first="Xiaoguang" last="Li">Xiaoguang Li</name>
</author>
<author><name sortKey="Xiao, Peng" sort="Xiao, Peng" uniqKey="Xiao P" first="Peng" last="Xiao">Peng Xiao</name>
</author>
<author><name sortKey="Tanaka, Takashi" sort="Tanaka, Takashi" uniqKey="Tanaka T" first="Takashi" last="Tanaka">Takashi Tanaka</name>
</author>
<author><name sortKey="Ling, Hong" sort="Ling, Hong" uniqKey="Ling H" first="Hong" last="Ling">Hong Ling</name>
</author>
<author><name sortKey="Yang, Baofeng" sort="Yang, Baofeng" uniqKey="Yang B" first="Baofeng" last="Yang">Baofeng Yang</name>
</author>
<author><name sortKey="Saitoh, Hiroki" sort="Saitoh, Hiroki" uniqKey="Saitoh H" first="Hiroki" last="Saitoh">Hiroki Saitoh</name>
</author>
<author><name sortKey="Zhang, Lianfeng" sort="Zhang, Lianfeng" uniqKey="Zhang L" first="Lianfeng" last="Zhang">Lianfeng Zhang</name>
</author>
<author><name sortKey="Qin, Chuan" sort="Qin, Chuan" uniqKey="Qin C" first="Chuan" last="Qin">Chuan Qin</name>
</author>
<author><name sortKey="Sugamura, Kazuo" sort="Sugamura, Kazuo" uniqKey="Sugamura K" first="Kazuo" last="Sugamura">Kazuo Sugamura</name>
</author>
<author><name sortKey="Hattori, Toshio" sort="Hattori, Toshio" uniqKey="Hattori T" first="Toshio" last="Hattori">Toshio Hattori</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19428598</idno>
<idno type="pmid">19428598</idno>
<idno type="doi">10.1016/j.antiviral.2009.02.001</idno>
<idno type="wicri:Area/PubMed/Corpus">001906</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001906</idno>
<idno type="wicri:Area/PubMed/Curation">001906</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001906</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001814</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001814</idno>
<idno type="wicri:Area/Ncbi/Merge">001F11</idno>
<idno type="wicri:Area/Ncbi/Curation">001F11</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001F11</idno>
<idno type="wicri:Area/Main/Merge">002A97</idno>
<idno type="wicri:Area/Main/Curation">002A50</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection.</title>
<author><name sortKey="Zhuang, Min" sort="Zhuang, Min" uniqKey="Zhuang M" first="Min" last="Zhuang">Min Zhuang</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University, 980-8574, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Emerging Infectious Diseases, Department of Internal Medicine, Tohoku University, 980-8574</wicri:regionArea>
<orgName type="university">Université du Tōhoku</orgName>
<placeName><settlement type="city">Sendai</settlement>
<region type="province">Région de Tōhoku</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jiang, Hong" sort="Jiang, Hong" uniqKey="Jiang H" first="Hong" last="Jiang">Hong Jiang</name>
</author>
<author><name sortKey="Suzuki, Yasuhiro" sort="Suzuki, Yasuhiro" uniqKey="Suzuki Y" first="Yasuhiro" last="Suzuki">Yasuhiro Suzuki</name>
</author>
<author><name sortKey="Li, Xiaoguang" sort="Li, Xiaoguang" uniqKey="Li X" first="Xiaoguang" last="Li">Xiaoguang Li</name>
</author>
<author><name sortKey="Xiao, Peng" sort="Xiao, Peng" uniqKey="Xiao P" first="Peng" last="Xiao">Peng Xiao</name>
</author>
<author><name sortKey="Tanaka, Takashi" sort="Tanaka, Takashi" uniqKey="Tanaka T" first="Takashi" last="Tanaka">Takashi Tanaka</name>
</author>
<author><name sortKey="Ling, Hong" sort="Ling, Hong" uniqKey="Ling H" first="Hong" last="Ling">Hong Ling</name>
</author>
<author><name sortKey="Yang, Baofeng" sort="Yang, Baofeng" uniqKey="Yang B" first="Baofeng" last="Yang">Baofeng Yang</name>
</author>
<author><name sortKey="Saitoh, Hiroki" sort="Saitoh, Hiroki" uniqKey="Saitoh H" first="Hiroki" last="Saitoh">Hiroki Saitoh</name>
</author>
<author><name sortKey="Zhang, Lianfeng" sort="Zhang, Lianfeng" uniqKey="Zhang L" first="Lianfeng" last="Zhang">Lianfeng Zhang</name>
</author>
<author><name sortKey="Qin, Chuan" sort="Qin, Chuan" uniqKey="Qin C" first="Chuan" last="Qin">Chuan Qin</name>
</author>
<author><name sortKey="Sugamura, Kazuo" sort="Sugamura, Kazuo" uniqKey="Sugamura K" first="Kazuo" last="Sugamura">Kazuo Sugamura</name>
</author>
<author><name sortKey="Hattori, Toshio" sort="Hattori, Toshio" uniqKey="Hattori T" first="Toshio" last="Hattori">Toshio Hattori</name>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Butanols (chemistry)</term>
<term>Cell Line</term>
<term>Down-Regulation</term>
<term>Drugs, Chinese Herbal (chemistry)</term>
<term>Drugs, Chinese Herbal (pharmacology)</term>
<term>Humans</term>
<term>Plants, Medicinal (chemistry)</term>
<term>Proanthocyanidins (chemistry)</term>
<term>Proanthocyanidins (pharmacology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Butanols ()</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Médicaments issus de plantes chinoises ()</term>
<term>Médicaments issus de plantes chinoises (pharmacologie)</term>
<term>Plantes médicinales ()</term>
<term>Proanthocyanidines ()</term>
<term>Proanthocyanidines (pharmacologie)</term>
<term>Régulation négative</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Butanols</term>
<term>Drugs, Chinese Herbal</term>
<term>Proanthocyanidins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Drugs, Chinese Herbal</term>
<term>Proanthocyanidins</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Plants, Medicinal</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Médicaments issus de plantes chinoises</term>
<term>Proanthocyanidines</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Line</term>
<term>Down-Regulation</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Butanols</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Médicaments issus de plantes chinoises</term>
<term>Plantes médicinales</term>
<term>Proanthocyanidines</term>
<term>Régulation négative</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We found that the butanol fraction of Cinnamomi Cortex (CC/Fr.2) showed moderate inhibitory activity in wild-type severe acute respiratory syndrome coronavirus (wtSARS-CoV) and HIV/SARS-CoV S pseudovirus infections. The inhibition on pseudovirus was also seen in cells pretreated with the CC and CC/Fr.2 (IC(50S), 283.4+/-16.3 and 149.5+/-13.5 microg/ml, respectively), however the highest activities on wtSARS-CoV were observed when the viruses were treated by the extracts before challenging (IC(50S), 43.1+/-2.8 and 7.8+/-0.3 microg/ml; SIs, 8.4 and 23.1, respectively). Among the compounds fractionated from CC, procyanidin A2 and procyanidin B1 showed moderate anti-wtSARS-CoV activity (IC(50S), 29.9+/-3.3 and 41.3+/-3.4 microM; SIs, 37.35 and 15.69, respectively). We also sought to determine whether they could interfere with the clathrin-dependent endocytosis pathway using transferrin receptor (TfR) as an indicator. CC/Fr.2 inhibited the internalization of TfR but the procyanidins did not. Taken together, CC/Fr.2 contains unknown substances, that could inhibit the infection, probably by interfering with endocytosis, and it also contains procyanidins that did not inhibit the internalization but inhibited the infection. Therefore, CC extracts contain anti-virus activities that act through distinct mechanisms according to differences in the compounds or mixtures.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002A50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:19428598 |texte= Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:19428598" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |